Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. - Wikidata - awgldk - TriplyDB

Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.

Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.

http://www.wikidata.org/entity/Q35760171

about

Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives Use of biologics in SLE: a review of the evidence from a clinical perspective Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics Prospective data collection of off-label use of rituximab in Australian public hospitals.Cognitive dysfunction and functional magnetic resonance imaging in systemic lupus erythematosus.The potential utility of B cell-directed biologic therapy in autoimmune diseases.Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.Two negative randomized controlled trials in lupus: now what?Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches.Psychosis in a young female - a diagnostic and therapeutic challenge.The emerging role of autoimmunity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/cfs).Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration.Autoantibody-mediated disorders of the central nervous system.Central nervous system vasculitis: still more questions than answers.Mechanisms of B cell autoimmunity in SLE.Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study.Contemporary treatment of systemic lupus erythematosus: an update for clinicians.Parkinsonism can be cured.B cell and/or autoantibody deficiency do not prevent neuropsychiatric disease in murine systemic lupus erythematosus B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family.Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms.Single dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome.Treating patients with lupus with B-cell depletion.A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study.SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus.Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease.Effects of rituximab on resistant SLE disease including lung involvement.Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response Effect of B-cell depletion on viral replication and clinical outcome of simian immunodeficiency virus infection in a natural host.CD40 and autoimmunity: the dark side of a great activator.Temporal requirements for B cells in the establishment of CD4 T cell memory.Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets.Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases.Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy.Pathogenesis of neuropsychiatric systemic lupus erythematosus and potential biomarkers.Update on emerging drug therapies for systemic lupus erythematosus.

P2860

Q26774815-CD554A3A-CA2D-49EC-89A1-D202C77AB990 Q26783652-DEB6BE0A-760E-4A7C-A70D-F3A6FE0E6CA7 Q26998412-EE7BC557-21DE-400A-BBBB-55F376A26F2B Q30640279-ED4C4B76-FF71-4E27-828C-ACBF4A9055ED Q30977603-50D35E5D-5A41-4332-A20E-A04F0EA1CF70 Q33377109-17852597-5945-4A49-A678-FBFC82C87557 Q33387348-D7155651-98E5-4FB2-80CA-0CC1EDE601E0 Q34076412-51BA3A0C-C357-4AA6-80E3-11B8DA71DCF0 Q34087831-6DF6819F-BD05-4ABE-BE33-D18A8162FAF6 Q34170097-AAC775F8-32A7-4A74-96DA-6C54C2DB2103 Q34321259-FEECC534-001A-49CF-8CA2-2F70CD5925A5 Q34373452-C073825A-4811-494F-BF1A-5E758ACD15DB Q34463760-067FF9E0-F4C3-4F49-B66D-00AADC2B6CAA Q34733326-2E0E47DD-63F5-4A96-BF54-6F769FBEBC2B Q35151866-CB77F1A5-9A64-4BC7-993E-588D5B8F665A Q35840704-71EDB7BF-8597-4A15-851E-AA9D470F9F38 Q35993027-7756FBD6-943A-4557-9CE5-8180D73C9C63 Q36171750-FA9EAC12-D501-4A93-A0B9-243B575AB35F Q36219954-36A1B358-319C-4340-B4E2-D244F966C896 Q36307414-D82B3DB3-5682-451F-A436-7BA7C776D73C Q36443689-41F9ADDC-9B90-4FC8-B2B1-8EDF58A799D7 Q36705129-E822F9D5-514F-45C7-BF29-8A8B2B4CE3D8 Q36774762-E4D8DF6B-1E9E-44F3-A949-1A446431AF47 Q36897408-4E9D12C3-DDD4-48D8-BA1B-B97A93A77765 Q36955326-6A768605-D4AD-488A-926A-39D134DC28FA Q37108328-4C09F416-46AC-47C4-A99F-5BB5CB46E373 Q37168014-6FFFF5CC-7712-4D75-B168-A8892C3EA956 Q37203531-C07809EC-80D4-4908-9E89-6E552B111CDE Q37226689-59C636D3-309E-46F1-A372-F5023AB4CE80 Q37227988-3E13A410-A7E5-46B4-883E-51B2115103A5 Q37346769-31834281-8A97-43DF-8908-7EDF9E75F487 Q37350960-5424E399-2C70-480C-9797-DFD82A726993 Q37365356-1679F588-01C9-4C99-8039-82F2E8E07418 Q37365433-CECE8AA7-70B0-415B-A46F-3E2AB0F5F76B Q37399047-4F3E038C-725C-4314-8046-4FD889D5B3A0 Q37436035-7C0A5269-8C13-4161-BCA4-77E6700F0E40 Q37541561-33B01DA5-E4CD-4354-86A0-36D1A106B122 Q37552019-0785820C-F47B-48D1-BFE0-438E6B00A66B Q37556128-2F62521A-71CC-4987-879D-2F2CA3AC0718 Q37690745-1EA1ACBB-B064-48E0-9679-4C4FAA3A3BD6

P2860

Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.

http://www.wikidata.org/entity/Q35760171

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Efficacy of rituximab (anti-CD ...... ng the central nervous system.

@ast

Efficacy of rituximab (anti-CD ...... ng the central nervous system.

@en

type

label

Efficacy of rituximab (anti-CD ...... ng the central nervous system.

@ast

Efficacy of rituximab (anti-CD ...... ng the central nervous system.

@en

prefLabel

Efficacy of rituximab (anti-CD ...... ng the central nervous system.

@ast

Efficacy of rituximab (anti-CD ...... ng the central nervous system.

@en

P1433

Q35760171-406E2E25-C7BA-40B1-8738-9AA9BB5811E3

P1476

Q35760171-16246C7D-6FB7-4E93-AF25-4C24B271CC02

P2093

Q35760171-0DCFD2A9-2676-433E-82CD-A925F2160D15

Q35760171-10A37E54-C165-462E-914E-B6FDC53D9441

Q35760171-35DD2885-865C-400E-9B6A-D2083769FA61

Q35760171-44D3FFC9-C5B4-44A8-9916-79057ACAD91C

Q35760171-570564FA-FB7D-4A13-BC7C-DCDF7FDF5C57

Q35760171-5E6FAAD9-170A-4DFE-9C05-2E4095E7A982

Q35760171-660D14A1-8B94-4B7F-A2E5-F1D1FB335376

Q35760171-76DF7911-66AF-4300-AFBA-76F41F26C88F

Q35760171-792E8B32-CB66-44BC-807B-3C4A4CBD6E77

Q35760171-9A44E7E8-B054-4639-9341-0B1CD5A515DD

P2860

Q35760171-015DE19D-9532-4C81-96A0-C3DAC90C048A

Q35760171-1006003A-6948-465A-904F-A51F3065714A

Q35760171-116F0DC8-F620-4AB2-9606-A4F2A09665BD

Q35760171-19699ADB-CC55-4FB5-9F6C-49F92EE3A31B

Q35760171-2229EC3C-E15A-4CB0-AD18-1C3ACD53A8CD

Q35760171-2B8FEF62-EDB8-44B2-AB31-BBCCCB61C3ED

Q35760171-2F2B6394-2D12-4B9C-A735-DA259B169158

Q35760171-515278F2-C9A2-40BB-A5ED-E552433E0C87

Q35760171-56FF3041-6DF9-4697-9831-7589544A33E7

Q35760171-65068F5B-A06D-4DF5-ACE2-2AFC93E0EE2D

P304

Q35760171-EE06338C-00C7-41F2-B812-1829B5210667

P31

Q35760171-061307E7-86CB-4A59-BF2C-E8005C635AF2

P356

Q35760171-73F46E1C-2A9C-4D30-B251-B6B0040DAD00

P407

Q35760171-A1DDA34F-DCFE-487E-ACFA-48CAAA20C30A

P433

Q35760171-CBA2DC7E-FA61-4658-9108-48D4F15E760B

P478

Q35760171-06176E08-80BC-4721-9D56-AFB4CB480D19

P577

Q35760171-2F44CF95-9625-4A4A-9F94-07FA334B0B12

P5875

Q35760171-55B19031-FBF8-487A-BD91-302E3DEC90F2

P698

Q35760171-3D04DD75-CAE3-4B45-94D2-BD3C02093B95

P932

Q35760171-B240ED54-527A-4656-B98F-76DF6C4EE9F8

P356

ARD.2006.057885

P1433

Annals of the Rheumatic Diseases

P1476

Efficacy of rituximab (anti-CD ...... ng the central nervous system.

@en

P2093

Daisuke Kawabata

http://www.w3.org/2001/XMLSchema#string

Kazuyoshi Saito

http://www.w3.org/2001/XMLSchema#string

Masao Nawata

http://www.w3.org/2001/XMLSchema#string

Mikiko Tokunaga

http://www.w3.org/2001/XMLSchema#string

Shigeru Iwata

http://www.w3.org/2001/XMLSchema#string

Shingo Nakayamada

http://www.w3.org/2001/XMLSchema#string

Shizuyo Tsujimura

http://www.w3.org/2001/XMLSchema#string

Taeko Azuma

http://www.w3.org/2001/XMLSchema#string

Takao Fujii

http://www.w3.org/2001/XMLSchema#string

Tsuneyo Mimori

http://www.w3.org/2001/XMLSchema#string

P2860

The 1982 revised criteria for the classification of systemic lupus erythematosus

T cells in the pathogenesis of systemic lupus erythematosus: potential roles of CD154-CD40 interactions and costimulatory molecules.

Causes of death and prognostic factors in Thai patients with systemic lupus erythematosus.

Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus

Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.

Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus.

Cyclophosphamide: new approaches for systemic lupus erythematosus.

Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus: report of a consensus meeting.

Neuropsychiatric features of systemic lupus erythematosus.

Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial

P304

470-475

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2006.057885

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P577

2006-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6689742

http://www.w3.org/2001/XMLSchema#string

P698

17107983

http://www.w3.org/2001/XMLSchema#string

P932

1856059

http://www.w3.org/2001/XMLSchema#string